Research Reports

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) Late- Stage Clinical Trials Substantiating Investor Interest

Thank You for Joining the most Reliable Source for Balanced Research Reports on the Markets Hottest Companies. 

At anytime you can visit our homepage under the Research Reports Tab to view our most recent reports.

Soon, You will be receiving an email that describes the efforts we take to create quality and balanced analyst reports for the investing public.

When we find a stock pick that meets or exceeds our criteria to qualify as a Stock Alert, we will send a detailed report to you describing the reasons why we have chosen this stock. 

NYMX Research Report Written by Mark Bonacci,

Chief Financial Analyst

Mark Bonacci has worked on Wall Street for several years in various financial services roles and is a

self-employed investment analyst and equity trader 

Published May 14, 2014

Use the PDF Icon provided below to get the full research report on NYMX.

PDFicon